We have located links that may give you full text access.
English Abstract
Journal Article
[Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
Zhonghua Gan Zang Bing za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology 2018 March 21
Chronic hepatitis C (CHC) has a prevalence rate of 0.43% in China and approximately 10 million chronically infected people are in urgent need of treatment. Since the beginning of 2013, pan-genotypic sofosbuvir (SOF) with its potent antiviral activity, minimal drug resistance, less drug-drug interactions and good safety has created a new era in HCV treatment. Its combination with ribavirin, in single tablet regimen with either ledipasvir or velpatasvir has been widely used in about 1.6 million patients worldwide. Furthermore, SOF-based therapy is proven to be effective and safe in serious or terminal illness such as decompensated cirrhosis, liver or kidney transplantation, HIV or HBV co-infections, bleeding disorders, intravenous drug users, adolescents, and elderly. Therefore, SOF-based regimens would fill the unmet medical needs of our patients with HCV.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app